David T Valenta
Overview
Explore the profile of David T Valenta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
391
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Werner S, Graf R, Landers M, Valenta D, Schroeder M, Greene S, et al.
J Circ Biomark
. 2017 Sep;
4:3.
PMID: 28936239
The Epic Platform was developed for the unbiased detection and molecular characterization of circulating tumour cells (CTCs). Here, we report assay performance data, including accuracy, linearity, specificity and intra/inter-assay precision...
2.
Sharma G, She Z, Valenta D, Stallcup W, Smith J
Nano Life
. 2012 Nov;
1(3-4):207-214.
PMID: 23125876
Macrophage foam cells are key components of atherosclerotic plaque and play an important role in the progression of atherosclerosis leading to plaque rupture and thrombosis. Foam cells are emerging as...
3.
Ostertag D, Amundson K, Espinoza F, Martin B, Buckley T, Galvao da Silva A, et al.
Neuro Oncol
. 2011 Nov;
14(2):145-59.
PMID: 22070930
Patients with the most common and aggressive form of high-grade glioma, glioblastoma multiforme, have poor prognosis and few treatment options. In 2 immunocompetent mouse brain tumor models (CT26-BALB/c and Tu-2449-B6C3F1),...
4.
Sharma G, Valenta D, Altman Y, Harvey S, Xie H, Mitragotri S, et al.
J Control Release
. 2010 Aug;
147(3):408-12.
PMID: 20691741
The interaction of macrophages with micro and nanoparticles (MNPs) is important because these cells clear particles from the circulation, and because they are potential therapeutic targets in inflammatory conditions, atherosclerosis...
5.
Valenta D, Bulgrien J, Bonnet D, Curtiss L
J Lipid Res
. 2007 Oct;
49(1):24-32.
PMID: 17928634
Systemic phospholipid transfer protein (PLTP) is a recognized risk factor for coronary heart disease. In apolipoprotein E-deficient mice, systemic PLTP deficiency is atheroprotective, whereas PLTP overexpression is proatherogenic. As expected,...
6.
Valenta D, Ogier N, Bradshaw G, Black A, Bonnet D, Lagrost L, et al.
Arterioscler Thromb Vasc Biol
. 2006 May;
26(7):1572-8.
PMID: 16675720
Objective: Using bone marrow transplantation, we assessed the impact of macrophage-derived phospholipid transfer protein (PLTP) on lesion development in hypercholesterolemic mice that expressed either normal levels of mouse apolipoprotein AI...
7.
Valenta D, Bulgrien J, Banka C, Curtiss L
Atherosclerosis
. 2006 Jan;
189(2):255-63.
PMID: 16423356
The long-term effect of elevated levels of human apolipoprotein AI (apoAI) on atherosclerosis was assessed using human apoAI transgenic mice on a double mutant LDL receptor-deficient (LDLr-/-) and mouse apoAI-deficient...
8.
Curtiss L, Valenta D, Hime N, Rye K
Arterioscler Thromb Vasc Biol
. 2005 Nov;
26(1):12-9.
PMID: 16269660
An initial step in reverse cholesterol transport is the movement of unesterified cholesterol from peripheral cells to high-density lipoproteins (HDLs). This transfer usually occurs in extracellular spaces, such as the...